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Chronic lymphocytic leukemia (CLL) rarely exhibits an aggressive clinical course and its patients often have
chromosomal deletions or additions. Furthermore, reciprocal translocations are barely observed in CLL. There have
only been a few reports of CLL with t(1;6), and here we report the first Asian case of CLL with reciprocal
translocation t(1;6). Since our case and previously reported CLL patients with t(1;6) consistently showed aggressive
clinical course, t(1;6) may define a distinct type of CLL.
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Chronic lymphocytic leukemia (CLL) is a mature B-cell
neoplasm characterized by increased abnormal non-
large CD5+CD20+CD23+ B cells in peripheral blood,
bone marrow, and lymphoid organs [1,2]. CLL usually
exhibits an indolent clinical course, but sometimes
shows aggressive clinical course, including Richter’s
transformation with poor outcome. Poor prognosis in
CLL is associated with expression of CD38 or zeta-chain
associated protein-70 (ZAP-70), mutations and/or ex-
pression of tumor protein p53 (TP53), and abnormal
cytogenetics [3]. The majority of patients with CLL have
chromosomal deletions or additions, but chromosomal
translocations are rare, and if present, they are usually
associated with the loci of immunoglobulin (IG) genes,
14q32, 2p13, or 22q11 [4]. Also, information on the roles
of these translocations in clinical outcome or pathogen-
esis is extremely limited in CLL.
There are only a few reports of translocation t(1;6)
involving chromosome 6p25~ 23 in patients with CLL
[5-9]. This type of translocation was observed in ap-
proximately 0.5% of patients with CLL in the Belgian
databases [5]. These cases showed an aggressive clinical
course. Furthermore, when treated with purine analo-
gues, patients often develop Richter’s transformation. It* Correspondence: kazu-ike@fmu.ac.jp
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ation, interferon regulatory factor 4 (IRF4) gene on
6p25, correlates with the pathogenesis of CLL cases
with t (1;6) [5].
Here, we report the first Asian case of CLL with trans-
location t(1;6) where CLL cells expressed IRF4. The pa-
tient showed an aggressive clinical course and was
successfully treated with conventional chemotherapy
without purine analogue.Case report
A 56-year-old Japanese male, who had taken medical la-
boratory examinations every half-year, was first found to
have a slightly elevated peripheral white blood cell count
(12 x 109/L) in July 2010, while showing no other abnor-
mal findings on blood examination and systemic posi-
tron emission tomography using 18 F-fluorodeoxy
glucose. However, only 2 months later he noticed a sys-
temic swelling of lymph nodes, which further rapidly
enlarged, and he developed a high body temperature and
night sweat. He had a supraclavicular lymph node biopsy
in November 2010, and was considered to have
advanced B-cell lymphoma because CD20+ lymphoid
cells proliferated. Based on this finding, he was referred
to our department for the purpose of chemotherapy. On
admission, he had mild splenomegaly and leukocytosis
(17 x 109/L), and his platelet count and hemoglobin con-
centration were normal. Abnormal lymphoid cells were
also present in the bone marrow (Figure 1). TheLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Histologic findings of bone marrow. May-Giemsa, H&E, and immunohistochemistrical stainings with indicated antibodies (x400) are
shown.
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bone marrow were 2.8% and 67.2%, respectively. He im-
mediately received chemotherapy consisting of cyclo-
phosphamide, vincristine, doxorubicin, dexamethasone,
and rituximab (R-hyper-CVAD) [10,11], resulting in
complete remission. After finishing this initial treatment,
it turned out that the majority of proliferated lymphoid
cells in the samples taken before treatment were positive
for CD5, CD23, CD38, B-cell lymphoma (BCL)-2, as well
as CD20, and negative for CD3, CD10, CD56, Cyclin D1,
Cyclin D2, TP53, and terminal deoxynucleotidyl trans-
ferase in immunohistochemistry and/or flow cytometry.
Both IRF-4 and ZAP-70, but not TP53, were strongly
expressed in the lymphoid cells (Figure 1), and approxi-
mately 10% of the cells were positive for Ki67. We then
reconfirmed that there were few large cells in each sam-
ple of peripheral blood, bone marrow, and the biopsied
lymph node. Based on these morphological findings and
the immune phenotype, he was diagnosed with CLL
without the Richter’s transformation. According to the
diagnosis of CLL, clinical stage before the initial treat-
ment was reestablished as the Binet B and Rai II. Cyto-
genetic analysis with the G-banding method without the
addition of mitogen revealed a chromosomal transloca-
tion, 46,XY,t(1;6)(p34.1;p23) in 10 of 20 analyzed meta-
phase cells (Figure 2). No other abnormality was found
with chromosomal analysis with G-banding, and del11q
was not detected in FISH analysis. He received a total
of 6 courses of R-hyper-CVAD and high-dose chemo-
therapy with ranimustine, cytarabine, etoposide, andmelphalan, followed by autologous peripheral blood
stem cell transplantation (auto-PBSCT). Since then, his
CLL has not relapsed for 20 months.
Discussion
Chromosomal translocations are rare but usually involve
the IG genes in CLL [4]. However, our patient showed
the reciprocal chromosomal translocation t (1;6)(p34.1;
p23), which is not associated with the IG genes. So far,
there have been a few reports on t (1;6) in CLL, includ-
ing a study on 8 patients with the t(1;6)(p36 ~ 33;
p25 ~ 23) found in the Belgian Cytogenetic Institutes
database [5]. The 8 patients showed an advanced and
progressive clinical course, with three of them being
complicated with Richter’s transformation. In addition,
most of these patients required conventional chemother-
apy shortly after diagnosis. Our patient also showed
rapid progression of the disease after the sudden onset.
CLL cases with t (1;6)(p35;p25) in the complex karyo-
type have also been reported [7,8]. Thus, CLL with t
(1;6) may be of a distinct type. On the other hand, there
have been more CLL cases with t(1;6) who had different
breakpoints such as 1q25, 1q21, 6p11 and 6p12 [9], but
the features of these cases remain unknown.
The CLL cells in our case significantly expressed IRF4
in immunohistochemistry. CLL cells are known to fre-
quently express IRF4 [12], which was also implicated in
the pathogenesis of CLL with t(1;6) [5]. However, IRF4
expression in the patients with t(1;6) has not been
shown in the previous reports. Overexpression of IRF4
Figure 2 The G-banding shows 46,XY,t(1;6)(p34.1;p23).
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the IRF4 gene [13], but unfortunately, genetic analysis
for IRF4 was not performed in our case. Whether
chromosomal rearrangement of t(1;6) is inducible to ex-
press IRF4 as well as the somatic point mutation in the
IRF4 gene remains unclear.
Our case also showed robust expression of ZAP-70
(Figure 1), which is associated with poor prognosis and
aggressive clinical course in CLL. The immunoglobulin
variable heavy chain (IgVH) gene was not investigated in
our case, as it is known that the expression of ZAP-70 is
strongly correlated with the unmutated IgVH gene [14].
Interestingly, almost all CLL patients with t(1;6) exhib-
ited the unmutated IgHV gene [5]. As for other predic-
tors of poor prognosis, CD38, but not TP53 or Ki67,
was significantly expressed in our case.
The most common treatment for CLL is chemother-
apy with a purine analogue, although high-dose chemo-
therapy with auto-PBSCT may be another option if a
patient responds to conventional chemotherapy [15]. In
the previous report of CLL with t(1;6) by Michaux et al.
[5], 2 of 8 patients also underwent high-dose chemother-
apy with auto-PBSCT. Notably, both of them achieved
complete remission and their disease did not relapse
during observation. In contrast, of the 8 CLL patients
with t(1;6), patients who received purine analogues were
especially complicated with Richter’s transformation.
Proceeding from these findings and good response to
the initial treatment, our patient received a total of 6
courses of R-hyper-CVAD followed by high-dose chemo-
therapy with auto-PBSCT. However, owing to the limita-
tion in the number of patients, appropriate treatment
for CLL with t(1;6) remains to be determined.
In conclusion, we report the presence of CLL with t
(1;6) in Asians as well as Europeans, suggesting that t(1;6) may define a distinct type of CLL. We should an-
ticipate chromosomal abnormalities such as t(1;6) in
CLL as the prognosis may be affected.
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